Q-omics provides the consensus-scored GRSF1 profile across patient tissues and cancer cell-line models. GRSF1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, GRSF1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, GRSF1 protein abundance shows 26,206 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight CESC, HNSC, and LSCC as cancer lineages where GRSF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRSF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRSF1 survival associations across molecular data types. GRSF1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRSF1 RNA expression–survival associations across cancer types. High GRSF1 expression shows unfavorable associations in CESC, HNSC and LIHC, but favorable associations in COAD, KIRC and READ. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for GRSF1 RNA expression.
This table summarizes GRSF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GRSF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRSF1 shows higher tumor expression in HNSC, LIHC, STAD, LUSC, BRCA and CHOL. The HNSC box plot shows higher GRSF1 RNA expression in tumor versus normal tissue (log2 FC = +0.437, t-test p < 0.001).
This table shows molecular features associated with GRSF1 in patient tissues and cancer cell lines. In patient samples, GRSF1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GRSF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
